Tirzepatide, a novel medication agent, has emerged as a groundbreaking Lixisenatide innovation in the realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously binding both the GLP-1 and GIP receptors. This dual mechanism of action contributes to a pronounced reduction in glucose leve